Quality assurance is ensuring health products – everything from medication to microscopes – purchased and used by Global Fund-supported programs are safe, effective, of good quality and available to the patient.
Quality assurance at the Global Fund includes a framework of processes, standards and requirements that apply to products as well as practices.
For supply chain management, this means ensuring that:
Key stakeholders in quality assurance include:
The Global Fund maintains quality assurance policies for pharmaceutical products, for diagnostic products and for other health products:
In addition to following these policies, Principal Recipients must ensure that all pharmaceutical products are procured in accordance with the principles set out in the Model Quality Assurance System for Procurement Agencies interagency guidelines, available below for download.
Pharmaceuticals and other health products procured with Global Fund funds must comply with national regulations and, where applicable, be authorized by the national drug regulatory authority in the country in which they are used, following its standard practices for registration (or other forms of authorization, such as authorizations for special use).
In using pharmaceuticals, Principal Recipients are also expected to maintain pharmacovigilance – the detection, assessment and prevention of adverse effects of medicines or any other possible drug-related problems. Pharmacovigilance is a critical concern, as it affects the assessment of the risks and benefits possible in deploying new medicines for large-scale use. Pharmacovigilance enhances program effectiveness as well as the safety and quality of medicines.